Efficacy of hyperbaric oxygen therapy combined with mild hyperthermia for improving the anti-tumour effects of carboplatin

Abstract

The administration of HBO increased the effects of hyperthermic chemosensitisation to carboplatin at mild temperatures on experimental tumours, particularly when given in the sequence of carboplatin, mild HT, and HBO, a finding that supports previous clinical outcomes for a novel combined therapy using carboplatin plus HT and HBO.

Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer

“…Hyperthermia per se is cytotoxic at temperatures >43 C and HBOT exploits the reliance of tumor cells on glycolysis, a major contributor to the upregulation of antioxidant activity responsible for the increased resistance of the tumor to prooxidant chemotherapy and radiation therapies [93]. The synergism between these therapies (ketogenic diet, hyperthermia, HBOT) [23,26,[33][34][35][36] and their effectiveness in increasing the efficacy of conventional therapies have been reported in several studies [26,[35][36][37][38][39][40][41][51][52][53][54]. In NSCLC patients, Ohguri et al administered carboplatin/paclitaxel chemotherapy regimen together with hyperthermia and HBOT; and they reported the protocol as being a feasible and promising modality for treating NSCLC patients [35].…”

“…HBOT and hyperthermia was given the same day or the next day sequentially after chemotherapy. Preferentially, hyperthermia was given first, but the two were never given at the same time [35,36]. Patient and survival data were extracted from the records and analyzed.…”

“…Hyperthermia, locally increasing body temperature to 42 C or higher, exploits heat sensitivity of cancer cells and causes direct cytotoxicity. Hyperthermia has been shown to increase the efficacy of radiotherapy and some chemotherapeutic agents by sensitizing cancer cells to these therapies; and some chemotherapeutic agents have shown synergism with hyperthermia, including both carboplatin and paclitaxel [25,26,[35][36][37][38][39][40][41][42][43].…”

“…Administration of oxygen at elevated pressure during hyperbaric oxygen therapy (HBOT) results in better oxygenation of tumor cells; thus, counteracting unfavorable consequences of hypoxia. Several experimental studies provided supporting evidence for its potential use [33,34,[49][50][51][52][53]; and a number of clinical studies demonstrated its benefit when used in combination with chemotherapy and radiotherapy for the treatment of various malignancies [35,36,54].…”

Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours

“…HBO treatment overcomes tissue hypoxia and promotes the development of new blood vessels, which are then able to transport drug molecules, thereby rendering the tumour cells more sensitive to chemotherapeutic treatments. Several studies have been conducted to examine the impact of hyperbaric oxygen as an adjuvant agent for use with chemotherapy [ 46 – 60 ]. Kalns et al [ 47 ] found that the effect of hyperbaric oxygen on the proliferation and sensitivity to chemotherapy of prostate cancer cells in vitro were dependent on the type of cell line.…”